Loading viewer...
conference
Format: PDF conference
Tonix Pharmaceuticals presented its clinical-stage fibromyalgia treatment TNX-102 SL, highlighting two positive Phase 3 trials with NDA filing expected in H2 2024 and FDA approval anticipated in H2 2025. The company is a CNS-focused biopharma with marketed migraine therapies and a pipeline including a biologic cocaine antidote with FDA Breakthrough Therapy Designation.
investor_presentation
48 Pages
conference
17 Pages
Royal Gold, Inc.
Keppel Infrastructure Trust 2024 UBS OneASEAN Summit
conferenceconference
47 Pages
Keppel Infrastructure Trust
EPA Regional Roadshow Burlington Vermont Funding Community Equity
conferenceconference
72 Pages
U.S. Environmental Protection Agency
Heritage-Crystal Clean HCCI 2019 ROTH Conference Investor Presentation
conferenceconference
36 Pages
Heritage Crystal Clean, Inc.